CD19 and B-cell neoplasm: Along with CD19, CD20 was historically one of the first protein targets for CAR T cell therapy [8,9] due to the prevalence of CD20-positive cancers among B cell neoplasms and the high surface density of CD20 on malignant B cells [10].